Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress
Provided By GlobeNewswire
Last update: May 12, 2025
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025
Read more at globenewswire.com29.38
-5.2 (-15.04%)
Find more stocks in the Stock Screener
MTSR Latest News and Analysis
6 days ago - ChartmillLet's uncover which stocks are experiencing notable gaps during today's session.Let's have a look at the gap up and gap down stocks in today's session.
6 days ago - ChartmillGet insights into the top gainers and losers of Monday's pre-market session.The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
